Materialise teams with DePuy Synthes to offer 3-D printed guides for craniomaxillofacial surgery

Materialise ($MTLS), which sells 3-D printing software and printing solutions to hospitals, has inked a deal with Johnson & Johnson’s ($JNJ) DePuy Synthes to offer patient-specific craniomaxillofacial implants.

Under the partnership, the implants will be offered through DePuy’s Trumatch CMF Solutions in Australia and Europe, with the exception of France. Patient-specific implants are not commercially available in the U.S. and Canada.

Materialiise offers a web-based system that includes 3-D surgical planning software and patient-specific surgical guides for CMF surgery. The system provides customized solutions that are in harmony with the morphology and physiology of each individual patient, the company said.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“Together with DePuy Synthes, we have successfully enabled better surgical outcomes through surgical planning and patient-specific guides, and are proud that this new collaboration will now empower even more CMF surgeons to discover the benefits of 3D-printed, patient-specific implants as well,” Wilfried Vancraen, Materialise founder and CEO, said in a statement.

The Belgium-based small-cap 3-D printing company has been busy establishing itself in the healthcare market. Earlier this year it struck a deal with private, family-owned orthopedics player Mathys, which was looking to add 3-D printed surgical shoulder guides to its line. 

The previous year, Materialise announced it was expanding its U.S. operations in order to capitalize on its Materialise Mimics Innovation Suite, which is intended to be used in hospitals to create 3-D printed anatomical models for a variety of procedures. The software works with all 3-D printing technologies and is cleared by the FDA, the company said.

- check out the release

Related Articles:
Materialise CEO calls for industry standards for 3-D printed medical devices
Materialise partners with Mathys to offer 3-D printed, personalized shoulder surgery guides
J&J’s DePuy buys shape-changing, minimally invasive small bone fixation tech startup


Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.